Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)
Simon J. Crabb(University of Southampton), Robert J. Jones(Beatson West of Scotland Cancer Centre), Sam Wilding(University Hospital Southampton NHS Foundation Trust), Amy Whitehead(University Hospital Southampton NHS Foundation Trust), Ellice Marwood(University Hospital Southampton NHS Foundation Trust), Amit Bahl(At Bristol), Karen Martin(University Hospital Southampton NHS Foundation Trust), Charlotte Westbury(Institute of Cancer Research), Josh Northey(University Hospital Southampton NHS Foundation Trust), Carolina Salinas-Souza(AstraZeneca (United Kingdom)), Satish Kumar(Singleton Hospital), Claire Rooney(AstraZeneca (United Kingdom)), Tony Elliott(The Christie Hospital), Emily Shaw(University Hospital Southampton NHS Foundation Trust), Alison Birtle(University of Lancashire), Santhanam Sundar(Nottingham University Hospitals NHS Trust), Vincent Khoo(The University of Texas MD Anderson Cancer Center), Gareth Griffiths(NIHR Evaluation Trials and Studies Coordinating Centre), Denise Dunkley(University Hospital Southampton NHS Foundation Trust), Christine Stephens(AstraZeneca (United Kingdom)), Michelle Light(University Hospital Southampton NHS Foundation Trust), Nichola Downs(University Hospital Southampton NHS Foundation Trust), Satinder Jagdev(Leeds Teaching Hospitals NHS Trust), Angus Robinson(Royal Sussex County Hospital)
Cited by 82
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k